These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 15228163)

  • 1. Pharmacogenetics of thiopurine S-methyltransferase and thiopurine therapy.
    Evans WE
    Ther Drug Monit; 2004 Apr; 26(2):186-91. PubMed ID: 15228163
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacogenomics: the inherited basis for interindividual differences in drug response.
    Evans WE; Johnson JA
    Annu Rev Genomics Hum Genet; 2001; 2():9-39. PubMed ID: 11701642
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thiopurine S-methyltransferase pharmacogenetics: insights, challenges and future directions.
    Wang L; Weinshilboum R
    Oncogene; 2006 Mar; 25(11):1629-38. PubMed ID: 16550163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacogenetics as a molecular basis for individualized drug therapy: the thiopurine S-methyltransferase paradigm.
    Krynetski EY; Evans WE
    Pharm Res; 1999 Mar; 16(3):342-9. PubMed ID: 10213363
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thiopurine S-methyltransferase pharmacogenetics in childhood acute lymphoblastic leukemia.
    Yang JJ; Bhojwani D
    Methods Mol Biol; 2013; 999():273-84. PubMed ID: 23666706
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thiopurine pharmacogenetics: clinical and molecular studies of thiopurine methyltransferase.
    Weinshilboum R
    Drug Metab Dispos; 2001 Apr; 29(4 Pt 2):601-5. PubMed ID: 11259360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacogenomics of drug-metabolizing enzymes and drug transporters in chemotherapy.
    Bosch TM
    Methods Mol Biol; 2008; 448():63-76. PubMed ID: 18370231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thiopurine S-methyltransferase pharmacogenetics: genotype to phenotype correlation in the Slovenian population.
    Milek M; Murn J; Jaksic Z; Lukac Bajalo J; Jazbec J; Mlinaric Rascan I
    Pharmacology; 2006; 77(3):105-14. PubMed ID: 16691038
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Methylation pharmacogenetics: thiopurine methyltransferase as a model system.
    Weinshilboum RM
    Xenobiotica; 1992; 22(9-10):1055-71. PubMed ID: 1441597
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug methylation in cancer therapy: lessons from the TPMT polymorphism.
    Krynetski E; Evans WE
    Oncogene; 2003 Oct; 22(47):7403-13. PubMed ID: 14576848
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Utility of assessing thiopurine S-methyltransferase polymorphisms before azathioprine therapy.
    Cabaleiro T; Roman M; Gisbert JP; Abad-Santos F
    Curr Drug Metab; 2012 Nov; 13(9):1277-93. PubMed ID: 22493988
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancer pharmacogenomics: SNPs, chips, and the individual patient.
    McLeod HL; Yu J
    Cancer Invest; 2003; 21(4):630-40. PubMed ID: 14533451
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent advances in the pharmacogenomics of thiopurine methyltransferase.
    Coulthard SA; Hall AG
    Pharmacogenomics J; 2001; 1(4):254-61. PubMed ID: 11908768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacogenetics of thiopurines in inflammatory bowel disease.
    Derijks LJ; Wong DR
    Curr Pharm Des; 2010; 16(2):145-54. PubMed ID: 20205660
    [TBL] [Abstract][Full Text] [Related]  

  • 15. No induction of thiopurine methyltransferase during thiopurine treatment in inflammatory bowel disease.
    Lindqvist M; Hindorf U; Almer S; Söderkvist P; Ström M; Hjortswang H; Peterson C
    Nucleosides Nucleotides Nucleic Acids; 2006; 25(9-11):1033-7. PubMed ID: 17065060
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The thiopurine S-methyltransferase gene locus -- implications for clinical pharmacogenomics.
    McLeod HL; Siva C
    Pharmacogenomics; 2002 Jan; 3(1):89-98. PubMed ID: 11966406
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Are patients with intermediate TPMT activity at increased risk of myelosuppression when taking thiopurine medications?
    Higgs JE; Payne K; Roberts C; Newman WG
    Pharmacogenomics; 2010 Feb; 11(2):177-88. PubMed ID: 20136357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical pharmacology and pharmacogenetics of thiopurines.
    Sahasranaman S; Howard D; Roy S
    Eur J Clin Pharmacol; 2008 Aug; 64(8):753-67. PubMed ID: 18506437
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic polymorphisms of drug-metabolising enzymes and drug transporters in the chemotherapeutic treatment of cancer.
    Bosch TM; Meijerman I; Beijnen JH; Schellens JH
    Clin Pharmacokinet; 2006; 45(3):253-85. PubMed ID: 16509759
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease.
    Gearry RB; Barclay ML
    J Gastroenterol Hepatol; 2005 Aug; 20(8):1149-57. PubMed ID: 16048561
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.